Abstract

Bladder cancer is a challenging urological malignancy with a high likelihood of recurrence, making it difficult to treat. Metabolomics is a promising approach for the detection and treatment of bladder cancer, as it helps understand metabolic alterations linked to the disease. Metabolomics research uses two methodologies: immunohistochemistry and metabolomics. Metabolomics studies the metabolic patterns of biological material, including essential molecules like glucose, lipids, and amino acids. It serves several objectives, including biomarker discovery, pathway identification, and treatment targets. Immunohistochemistry is crucial in bladder cancer research, as it uses antibodies to identify and detect specific proteins in tissue samples. It helps in protein expression analysis, tumor microenvironment assessment, and classifying bladder cancer subtypes. Combining metabolomics and immunohistochemistry allows for a more profound understanding of the pathology, leading to improved therapy, diagnosis, and treatment. This comprehensive understanding of bladder cancer can lead to improved prognosis for those dealing with this complex ailment.

• 1.   Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin (2022) 72:7–33. doi: 10.3322/caac.217081
• 2.   Smith AB, Deal AM, Woods ME, Wallen EM, Pruthi RS, Chen RC, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the national cancer data base. BJU Int (2014) 114:719–26. doi: 10.1111/bju.12601)
• 3.   Lenis AT, Lec PM, Chamie K. Bladder cancer: A review. J Am Med Assoc. 2020;324(19):1980-91.
• 4.   Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al.Bladder cancer: Epidemiology, staging and grading, and diagnosis.Urology. 2005;66(6 Suppl 1):4-34.
• 5.   Akgul M, MacLennan GT, Cheng L. The applicability and utility of immunohistochemical biomarkers in bladder pathology. Hum Pathol. 2020;98:32-55.
• 6.   Witjes JA, Bruins HM, Carrión A, Cathomas R, Compérat EM, Efstathiou JA, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. In: EAU Annual Congress Amsterdam. Amsterdam: EAU Guidelines; 2022.
• 7.   Babjuk M, Burger M, Gontero P, Liedberg F, Palou J, van Rhijn BWG. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). In: EAU Annual Congress Amsterdam. Amsterdam: EAU Guidelines; 2022.
• 8.   Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med. 1941;47(2):200-2.
• 9.   Sukswai N, Khoury JD. Immunohistochemistry innovations for diagnosis and tissue-based biomarker detection. Curr Hematol Malig Rep. 2019;14(5):368-75.
• 10.   Razzaghdoust A, Ghajari M, Basiri A, Torbati PM, Jafari A, Fattahi M-R, et al. Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer markers of chemotherapy response in bladder cancer. Investig Clin Urol. 2021;62(3): 274-81.
• 11.   Cox RM, Magi-Galluzzi C, McKenney JK. Immunohistochemical pitfalls in genitourinary pathology: 2018 Update. Adv Anat Pathol. 2018;25(6):387-
• 12.   Akhtar M, Rashid S, Ben GM, Taha M, Al Bozom I. CK20 and CK5/6 immunohistochemical staining of urothelial neoplasms: A perspective. Adv Urol. 2020;2020;4920236.
• 13.   Ikeda J, Ohe C, Yoshida T, Kuroda N, Salto R, Kinoshita H, et al. Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumorassociated immune cell status in muscleinvasive bladder cancer. Pathol Int. 2021;71(3):173-82.
• 14.   Bejrananda T, Kanjanapradit K, Saetang J, Sangkhathat S. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscleinvasive bladder cancer. Sci Rep. 2021 Oct 27;11(1):21186. doi: 10.1038/s41598-021-00628-5. PMID: 34707176; PMCID: PMC8551252.
• 15.   Labban M, Najdi J, Mukherji D, Abou-Kheir W, Tabbarah A, El-Hajj A. Triple-marker immunohistochemical assessment of muscleinvasive bladder cancer: Is there prognostic significance? Cancer Reports (Hoboken). 2021;4(2):e1313.
• 16.   Choi W, Czerniak B, Ochoa A, Choi W, Czerniak B, Ochoa A, Su X, Siefher-Radtke A, Dinney C, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(7):400-10.
• 17.   Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152-65.
• 18.   Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefher-Radtke A, et al. Metaanalysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. eBioMedicine. 2016;12:105-17.
• 19.   Ranzi AD, da Silva JNL, Graziottin TM, Annels N, Bica CG. Immunohistochemistry biomarkers in nonmuscle invasive bladder cancer. Appl Immunohistochem Mol Morphol. 2017;25(3):178-83.
• 20.   Breyer J, Wirtz RM, Otto W, Erber P, Kriegmair MC, Stoehr R, et al. In stage pT1 Non-MuscleInvasive Bladder Cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch. 2017;470(3):267-74.
• 21.   Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefher-Radtke A, et al. Metaanalysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. eBioMedicine. 2016;12:105-17.
• 22.   Al-Sharaky DR, Abdelwahed M, Asaad N, Foda A, Abdou AG. Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20. J Immunoassay Immunochem. 2021;42(3):236-51.
• 23.   Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, et al. Assessment of luminal and basal phenotypes in bladder cancer. Sci Rep. 2020;10(1):9743.
• 24.   Lu J, Zhang Y, Wu C, Chu C, Liu Z, Cao Y. Impact of immunohistochemistry- based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment. Jpn J Clin Oncol. 2021;51(3):424-33.
• 25.   Hardy CSC, Ghaedi H, Slotman A, Sjödahl G, Gooding RJ, Berman DM, et al. Immunohistochemical assays for bladder cancer molecular subtyping: Optimizing parsimony and performance of lund taxonomy classifiers. J Histochem Cytochem. 2022;70(5):357-75.
• 26.   Yuk HD, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH. Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification. BMC Cancer. 2019;19 (1):897.
• 27.   Wang C-C, Tsai Y-C, Jeng Y-M. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer. PLoS One. 2019;14 (8):e0221785.
• 28.   Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild- type p53. Cell. 1992;70(6):923-35.
• 29.   Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31-46.
• 30.   da Silva JNL, Ranzi AD, Carvalho CT, Scheide TV, Strey YTM, Graziottin TM, et al. Cell cycle markers in the evaluation of bladder cancer. Pathol Oncol Res. 2020;26(1):175-81.
• 31.   Ziaran S, Harsanyi S, Bevizova K, Novakova ZV, Trebaticky B, Bujdak P, et al. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence. Eur J Histochem. 2020;64(2):3098.
• 32.   Daizumoto K, Yoshimaru T, Matsushita Y, Fukawa T, Uehara H, Ono M, et al. A DDX31/Mutant-p53/EGFR axis promotes multistep progression of muscle-invasive bladder cancer. Cancer Res. 2018;78(9):2233-47.
• 33.   Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006;24(35):5552-64. B, et al. Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urol Oncol. 2021;39(5):301. e17-301.e28.
• 34.   Semeniuk-Wojtaś A, Lubas A, Cierniak S, Brzóskowska U, Syryło T, Zieliński H, et al. Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer. J Cancer Res Clin Oncol. 2020;146(8):2099-108.
• 35.   Lloreta J, Font-Tello A, Juanpere N, Frances A, Lorenzo M, Nonell L, et al. FOXO1 downregulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression. Hum Pathol. 2017;62:222-31.
• 36.   Hodgson A, Rhijn BWG van, Kim SS, Ding C, Saleeb R, Vesprini D, et al. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. Pathol Res Pract. 2020;216(11):153186.
• 37.   Semeniuk-Wojtaś A, Lubas A, Cierniak S, Brzóskowska U, Syryło T, Zieliński H, et al. Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer. J Cancer Res Clin Oncol. 2020;146(8):2099-108.
• 38.   Han L, Gallan AJ, Steinberg GD, Sweis RF, Paner GP. Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Hum Pathol. 2020;106:54-61.
• 39.   Leivo MZ, Tacha DE, Hansel DE. Expression of uroplakin II and GATA- 3 in bladder cancer mimickers: Caveats in the use of a limited panel to determine cell of origin in bladder lesions. Hum Pathol. 2021;113:28-33.
• 40.   Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 Gene: A 185-kilodalton glycoprotem with tyrosine kinase activity. Science. 1986;232(4748):1644-6.
• 41.   Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37.
• 42.   Oh D-Y, Bang Y-J. HER2-targeted therapies - A role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33-48.
• 43.   Zhau HE, Zhang X, Von Eschenbach AC, Scorsone K, Babain RJ, Ro JY, et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 1990;3(5):254-7.
• 44.   Cimpean AM, Tarlui V, Cumpănaş AA, Bolintineanu S, Cumpănaş A, Raica M. Critical overview of HER2 assessement in bladder cancer: What is missing for a better therapeutic approach? Anticancer Res. 2017;37(9):4935-42.
• 45.   Cormio L, Sanguedolce F, Cormio A, Massenio P, Pedicillo MC, Cagiano S, et al. Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget. 2017;8(15):25433-41.
• 46.   Franceschini T, Capizzi E, Massari F, Schiavina R, Fiorentino M, GiunchiF. Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer. Pathol Res Pract. 2020;216(8):153012.
• 47.   Li W, Wang Y, Tan S, Rao Q, Zhu T, Huang G, et al. Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in bladder carcinoma and its association with patients’ clinical features. Med SciMonit. 2018;24:7178-85.
• 48.   Wucherpfennig S, Rose M, Maurer A, Cassataro MA, Seillier L, Morsch R, et al. Evaluation of therapeutic targets in histological subtypes of bladder cancer. Int J Mol Sci. 2021;22(21):11547.
• 49.   Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840.
• 50.   Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD- 1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-95.
• 51.   Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765-72.
• 52.   Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
• 53.   Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-20.
• 54.   Sisto M, Ribatti D, Lisi S, Kurien T. Cadherin signaling in cancer and autoimmune diseases. Int J Mol Sci. 2021;22(24):13358.
• 55.   Yu W, Yang L, Li T, Zhang Y. Cadherin signaling in cancer: Its functions and role as a therapeutic target. Front Oncol. 2019;9:989.
• 56.   Hussein S, Mosaad H, Rashed HE, Ahmed S, Ragab A, Ismail EI. Molecular factors regulating E-cadherin expression in urothelial bladder cancer and their correlations with the clinicopathological features. Mol Biol Rep. 2017;44(4):365-77.
• 57.   Hatina J, Schulz WA. Stem cells in the biology of normal urothelium and urothelial carcinoma. Neoplasma. 2012;59(6):728-36.
• 58.   Zhu F, Qian W, Zhang H, Liang Y, Wu M, Zhang Y, et al. SOX2 is a marker for stem-like tumor cells in bladder cancer. Stem Cell Rep. 2017;9(2):429- 37.
• 59.   Zhang S, Xiong X, Sun Y. Functional characterization of SOX2 as an anticancer target. Signal Transduct Target Ther. 2020;5(1):135.
• 60.   Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31(11):1354-65.
• 61.   Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, et al. Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2018;24(13):3069-78.
• 62.   Ruan J, Wei B, Xu Z, Yang S, Zhou Y, Yu M, et al. Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer. Med Oncol. 2013;30(1):445.
• 63.   Costa JB da, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, et al. Molecular characterization of neuroendocrinelike bladder cancer. Clin Cancer Res. 2019;25(13):3908-20.
• 64.   Belgorosky D, Girouard J, Langle YV, Hamelin-Morrissete J, Marino L, Agüero EI, et al. Relevance of iNOS expression in tumor growth and maintenance of cancer stem cells in a bladder cancer model. J Mol Med (Berl). 2020;98(11):1615-27.

Data Sharing Statement

Funding